Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program

Highlights ► We assessed effects of rosuvastatin on risk of developing renal impairment/failure. ► Participants were in rosuvastatin clinical development program. ► No effect on risk in patients without advanced, pre-existing renal disease.

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2012-04, Vol.221 (2), p.471-477
Main Authors: Stein, Evan A, Vidt, Donald G, Shepherd, James, Cain, Valerie A, Anzalone, Deborah, Cressman, Michael D
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
atherosclerosis
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Biomarkers - blood
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular
cholesterol
Cholesterol, LDL - blood
Clinical Trials as Topic
death
diabetes
Evidence-Based Medicine
Female
Fluorobenzenes - adverse effects
glomerular filtration rate
Glomerulonephritis
heart failure
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
hypertension
Kidney
Kidney - drug effects
Kidney - physiopathology
low density lipoprotein
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
patients
program planning
Proportional Hazards Models
Pyrimidines - adverse effects
relative risk
renal failure
Renal Insufficiency - chemically induced
Renal Insufficiency - physiopathology
Retrospective Studies
Risk Assessment
Risk Factors
Rosuvastatin
Rosuvastatin Calcium
Safety
Sulfonamides - adverse effects
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► We assessed effects of rosuvastatin on risk of developing renal impairment/failure. ► Participants were in rosuvastatin clinical development program. ► No effect on risk in patients without advanced, pre-existing renal disease.
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2011.12.011